Monoclonal antibodies to be integrated at the third dose in immunosuppressed and frail patients. It is a study ready to start at Inmi Spallanzani as announced by the director of Inmi Spallanzani in Rome, Francesco Vaia at the end of the meeting with the new interim scientific director, Enrico Girardi, and the director of the Clinical Department, Andrea Antinori. “In recent months, the Spallanzani Institute has conducted research on the vaccine response in various fragile populations, in people who are immunosuppressed for serious diseases or are treated with immunosuppressive therapies. Our goal, and of the country, is to guarantee protection from contagion also and especially to these people. We are doing this monoclonal access program that does not want to be an alternative, but to integrate. I have always said that there are two tools and that science will give us the answers. Some are working on the third dose “of the vaccine,” legitimately, and there are studies underway. We want to lend a hand, as a scientific institute. Without the ambition to be repositories of absolute truths, but we give our contribution “.
“In these days we have put in place a program to promote access to monoclonal antibodies to this type of population and we have submitted a monoclonal access program to the regulatory authorities and we are waiting this week for Aifa and the ethics committee to approve the program – Vaia specifies -. If everything goes well, as we hope, from Monday we will start administering the antibodies. As always, we will communicate the results of this innovative and stimulating application of research on the care level “.